Raptor Pharmaceutical Email Format

BiotechnologyUnited States51-200 Employees

Raptor Pharmaceutical Corp. is a United States-based biotechnology company focused on developing and commercializing therapies for rare, life-threatening diseases. Its program portfolio includes nephropathic cystinosis, Huntington’s disease, and mitochondrial disorders such as Leigh’s syndrome, with the aim of addressing significant unmet medical needs. The company holds orphan drug designations in the United States and Europe, including exclusive rights for nephropathic cystinosis and designation for Huntington’s disease, and it owns intellectual property related to the use of cysteamine in HD and other neurodegenerative disorders.

Raptor is headquartered in Novato, California, and operates as a mid-sized firm within the biopharmaceutical sector with a global orientation. In 2016, Horizon Therapeutics acquired Raptor Pharmaceutical, incorporating its programs into Horizon’s portfolio. The organization’s work is focused on delivering therapies for rare diseases, targeting patients and clinicians who manage these conditions.

Sign up for free to view info

Company overview Employee directory